RayKnowChina Research Map
Shortlist0

ShenyangChina Medical University (Shenyang)

First Hospital of China Medical University

中国医科大学附属第一医院

Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Hospital of China Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌7 papers led
  3. Hepatocellular carcinoma肝细胞癌61 papers led2 open trials led
  4. Stomach cancer胃癌109 papers led1 open trial led
  5. Chordoma脊索瘤0 papers led
  6. Osteosarcoma骨肉瘤5 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤6 papers led
  8. Neuroblastoma神经母细胞瘤2 papers led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤4 papers led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  12. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  13. Haemophilia A血友病 A1 paper led
  14. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  15. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病6 papers led
  16. IgG4-related diseaseIgG4相关性疾病6 papers led
  17. Myasthenia gravis重症肌无力9 papers led
  18. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  19. Takayasu arteritis大动脉炎0 papers led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  22. Fabry disease法布雷病0 papers led
  23. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  24. IgA nephropathyIgA 肾病4 papers led
  25. Osteogenesis imperfecta成骨不全症1 paper led
  26. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  27. Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
  28. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  29. Hereditary angioedema遗传性血管性水肿0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 222025

2 hospitals in Shenyang for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueSide effects & quality of lifeImmunotherapy
Departments in papersENT / head & neck surgeryRadiation oncology
Papers it led5
  1. PTEN as a prognostic factor for radiotherapy plus immunotherapy response in nasopharyngeal carcinoma.2025Journal of nanobiotechnologyFree full text
  2. CAPRIN1/TYMS/MTHFD2 axis promotes EMT process in nasopharyngeal carcinoma development.2025The international journal of biochemistry & cell biology
  3. Chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Who really needs it.2023Cancer medicineFree full text
  4. Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: A meta-analysis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. Effects of Baduanjin exercise in nasopharyngeal carcinoma patients after chemoradiotherapy: a randomized controlled trial.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
All its trials on ClinicalTrials.gov, any status1
  1. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
More papers found outside PubMed (not counted)5
  1. Assessment Tools for Health‐Related Quality of Life in Patients With Nasopharyngeal Carcinoma: A Systematic Review of Psychometric Properties2025European Journal of Cancer Carereview
  2. ctDNA-guided treatment stratification for nasopharyngeal carcinoma patients: A retrospective cohort.2025Journal of Clinical Oncologyarticle
  3. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figsharedataset
  4. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figsharereview
  5. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 7 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 0020222023: 2220232024: 1120242025: 002025

2 hospitals in Shenyang for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyMolecular markers & genomicsImmunotherapy
Departments in papersGastroenterology / hepatologyMedical oncologyRadiation oncology
Papers it led7
  1. Screening and verification of hub genes in esophageal squamous cell carcinoma by integrated analysis.2024Scientific reportsFree full text
  2. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.2023BMC cancerFree full text
  3. Mucosal esophageal carcinoma following endoscopic submucosal dissection with giant gastric metastasis: A case report and review of literature.2023World journal of gastroenterologyFree full text
  4. circRNA_141539 can serve as an oncogenic factor in esophageal squamous cell carcinoma by sponging miR-4469 and activating CDK3 gene.2021AgingFree full text
  5. LncRNA LINC00467 acted as an oncogene in esophageal squamous cell carcinoma by accelerating cell proliferation and preventing cell apoptosis via the miR-485-5p/DPAGT1 axis.2021Journal of gastroenterology and hepatology
  6. High expression of CIN85 promotes proliferation and invasion of human esophageal squamous cell carcinoma.2021Molecular medicine reportsFree full text
  7. Clinical analysis of 117 cases with synchronous multiple primary esophageal squamous cell carcinomas.2021The Korean journal of internal medicineFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  2. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  3. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Study sitePhase 3Start 2015-03
More papers found outside PubMed (not counted)26
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy.2025Journal of Clinical Oncologyconference-abstract
  3. 418P A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma2024Annals of Oncologyarticle
  4. The intricate mechanism through which UMODL1 accelerating tumor proliferation of Her-2 positive breast cancer as well as trastuzumab resistance2024Research Squarepreprint
  5. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncologyarticle
  6. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  7. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  8. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  9. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  10. Proper prognostic classification of histopathologic response to neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma2023Research Squarepreprint
  11. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  12. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  13. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  14. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  15. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  16. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  17. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  18. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  19. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  20. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  21. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset
  22. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  23. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  24. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  25. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  26. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 61 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
61
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 111120212022: 121220222023: 8820232024: 151520242025: 11112025

4 hospitals in Shenyang for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07483359

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  2. Not yet recruiting
    Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07557914

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  3. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  4. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  5. Recruiting
    Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07239245

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou

  6. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  7. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatology
Papers it led61
  1. Non-Gaussian diffusion MRI models for preoperative assessment of microvascular invasion in hepatocellular carcinoma.2026Abdominal radiology (New York)
  2. G6PD+CSV+ circulating tumor cells associated with portal vein tumor thrombus formation via EMT-ferroptosis crosstalk: a dual biomarker for therapeutic efficacy and prognosis prediction in hepatocellular carcinoma.2026Cancer letters
  3. Suppressing hyperthermia-induced up-regulated PD-L1 with a Sunitinib loaded Fe-Cu MOF: Strengthening immunogenic cell death to sensitize anti-PD-L1 effect following microwave ablation of hepatocellular carcinoma.2026Colloids and surfaces. B, Biointerfaces
  4. Research progress and therapeutic strategies in hepatocellular carcinoma metabolic reprogramming.2026Journal of advanced researchFree full text
  5. Balloon-occluded versus conventional transarterial chemoembolization for the treatment of early to intermediate stage hepatocellular carcinoma: a meta-analysis and trial sequential analysis.2025BMC cancerFree full text
  6. Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): st2025BMJ openFree full text
  7. The multifaceted roles of macrophages in the transition from hepatitis to hepatocellular carcinoma: From mechanisms to therapeutic strategies.2025Biochimica et biophysica acta. Molecular basis of disease
  8. Transcriptional regulation of ATOX1 by PRRX2 impacts the progression and cuproptosis of hepatocellular carcinoma.2025Cellular signalling
  9. Complications of transarterial radioembolization in hepatic malignancies: Pathophysiological insights and management paradigms.2025European journal of radiology
  10. CD63-high macrophage-derived exosomal miR-6876-5p promotes hepatocellular carcinoma stemness via PTEN/Akt-mediated EMT pathway.2025Hepatology communicationsFree full text
  11. In vitro anticancer effects in hepatocellular carcinoma (HCC) and protein interaction study of xanthoangelol.2025International journal of biological macromolecules
  12. MRI-based radiomics predicts complete responses to initial transcatheter arterial chemoembolization in virus-associated early and intermediate stage HCC.2025Magnetic resonance imaging
  13. Predicting the outcome of transarterial chemoembolization combined with targeted immunotherapy for unresectable hepatocellular carcinoma based on MRI radiomics.2025Scientific reportsFree full text
  14. NELL2 suppresses epithelial-mesenchymal transition and induces ferroptosis via notch signaling pathway in HCC.2025Scientific reportsFree full text
  15. Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models.2025World journal of gastroenterologyFree full text
  16. Deep Learning Model for Predicting Proliferative Hepatocellular Carcinoma Using Dynamic Contrast-Enhanced MRI: Implications for Early Recurrence Prediction Following Radical Resection.2024Academic radiology
  17. CD63 + tumor-associated macrophages drive the progression of hepatocellular carcinoma through the induction of epithelial-mesenchymal transition and lipid reprogramming.2024BMC cancerFree full text
  18. Long Noncoding RNAs MALAT1 and HOTTIP Act as Serum Biomarkers for Hepatocellular Carcinoma.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  19. The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions.2024Frontiers in immunologyFree full text
  20. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.2024Frontiers in immunologyFree full text
  21. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.2024Hepatology international
  22. The hepatic steatosis, steatohepatitis and metabolic dysfunction: distinct roles in hepatocellular carcinoma occurrence in chronic hepatitis B patients.2024Hepatology internationalFree full text
  23. Identification of PPAR-related differentially expressed genes liver hepatocellular carcinoma and construction of a prognostic model based on data analysis and molecular docking.2024Journal of cellular and molecular medicineFree full text
  24. Hemoglobin nanoclusters-mediated regulation of KPNA4 in hypoxic tumor microenvironment enhances photodynamic therapy in hepatocellular carcinoma.2024Journal of nanobiotechnologyFree full text
  25. Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors.2024Journal of natural products
  26. Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.2024Lancet (London, England)
  27. Nicotinamide mononucleotide induces autophagy and ferroptosis via AMPK/mTOR pathway in hepatocellular carcinoma.2024Molecular carcinogenesis
  28. Multimodal Theranostic Nanoparticles for Necrosis Targeting, Fluorescence/SPECT Imaging, and Radiotherapy of Residual Tumors after Hepatocellular Carcinoma Ablation.2024Molecular pharmaceutics
  29. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.2024Pharmacology & therapeutics
  30. Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  31. Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinoma.2023Cancer medicineFree full text
  32. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.2023Cancer metastasis reviews
  33. Survival benefit of perioperative locoregional adjuvant treatment for hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and Bayesian network meta-analysis.2023Critical reviews in oncology/hematology
  34. Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study.2023Expert review of anticancer therapy
  35. Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  36. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.2023Human cell
  37. CDK1-SRC Interaction-Dependent Transcriptional Activation of HSP90AB1 Promotes Antitumor Immunity in Hepatocellular Carcinoma.2023Journal of proteome research
  38. Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?2023Molecular cancerFree full text
  39. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.2022AgingFree full text
  40. Nomogram-based development and evaluation for predictions of 30-day and 1-year survival in patients with spontaneously ruptured hepatocellular carcinoma.2022BMC cancerFree full text
  41. Tumor and peritumor radiomics analysis based on contrast-enhanced CT for predicting early and late recurrence of hepatocellular carcinoma after liver resection.2022BMC cancerFree full text
  42. miR-3168 promotes hepatocellular carcinoma progression via downregulating p53.2022Carcinogenesis
  43. miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4α.2022Carcinogenesis
  44. Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.2022Cell death & diseaseFree full text
  45. Predicting Prognosis of Hepatocellular Carcinoma Patients Based on the Expression Signatures of Mitophagy Genes.2022Disease markersFree full text
  46. Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma.2022Hepatology internationalFree full text
  47. A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients.2022IET systems biologyFree full text
  48. Mig-6 Inhibits Autophagy in HCC Cell Lines by Modulating miR-193a-3p.2022International journal of medical sciencesFree full text
  49. Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review).2022International journal of oncologyFree full text
  50. Identification of the Mechanism of Matrine Combined with Glycyrrhizin for Hepatocellular Carcinoma Treatment through Network Pharmacology and Bioinformatics Analysis.2022Oxidative medicine and cellular longevityFree full text
  51. Evaluation of the efficacy and postoperative outcomes of hydrodissection-assisted microwave ablation for subcapsular hepatocellular carcinoma and colorectal liver metastases.2021Abdominal radiology (New York)
  52. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study.2021BMC cancerFree full text
  53. Brachytherapy with Iodine-125 seeds for treatment of portal vein-branch tumor thrombus in patients with hepatocellular carcinoma.2021BMC cancerFree full text
  54. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.2021Cancer scienceFree full text
  55. Aloin decelerates the progression of hepatocellular carcinoma through circ_0011385/miR-149-5p/WT1 axis.2021Cell cycle (Georgetown, Tex.)Free full text
  56. MicroRNA-1178-3p suppresses the growth of hepatocellular carcinoma by regulating transducin (beta)-like 1 X-linked receptor 1.2021Human cell
  57. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.2021International journal of nanomedicineFree full text
  58. Impact of low serum hemoglobin on development of contrast-induced nephropathy (CIN) in patients with hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE).2021International urology and nephrology
  59. Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma.2021Journal of biomedical nanotechnology
  60. Identification of CD8+ T Cell-Related Genes: Correlations with Immune Phenotypes and Outcomes of Liver Cancer.2021Journal of immunology researchFree full text
  61. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review.2021MedicineFree full text
All its trials on ClinicalTrials.gov, any status17
  1. Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor ThrombusRecruitingNCT07483359Lead sponsorPhase 2Start 2026-05
  2. HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCCStatus unknownNCT06632106Lead sponsorStart 2024-08
  3. HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLCStatus unknownNCT06632093Lead sponsorStart 2024-09
  4. HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)CompletedNCT06631326Lead sponsorStart 2021-01
  5. Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCCStatus unknownNCT02018757Lead sponsorPhase 2Start 2014-01
  6. Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNot yet recruitingNCT07557914Lead (inferred)Phase 2Start 2026-10
  7. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  8. Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoRecruitingNCT07239245Study sitePhase 2Start 2025-11
  9. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  10. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  11. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  12. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  13. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  14. Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCCStatus unknownNCT05339321Study sitePhase 1Start 2021-04
  15. A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsActive, not recruitingNCT06239155Study sitePhase 1/Phase 2Start 2019-09
  16. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  17. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownNCT03313596Study sitePhase 3Start 2013-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 109 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.

Papers led
109
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 303020212022: 212120222023: 161620232024: 202020242025: 19192025

5 hospitals in Shenyang for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06666166

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  2. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  3. Recruiting
    Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06830018

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  4. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

  5. Recruiting
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-08
    Registry
    NCT06504732

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang

  6. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  7. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  8. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  9. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

  10. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImaging & AIImmunotherapy & targeted drugs
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicine
Papers it led109
  1. Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Comparative short-term outcomes of peri-operative immunotherapy and targeted therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Gastric cancer causing Schnitzler's metastasis: case report and systematic review of the features.2025Acta oncologica (Stockholm, Sweden)Free full text
  4. Frailty as a predictor of postoperative outcomes in older gastroesophageal cancer patients: a systematic review and meta-analysis.2025BMC geriatricsFree full text
  5. Helicobacter pylori SlyD stabilizes TPT1 via hnRNPK and enhances OCT1-mediated CDX2 transcriptional activation to drive gastric intestinal metaplasia.2025BMC medicineFree full text
  6. Advanced ensemble staking model employing cfDNA fragmentation for early detection of esophageal and gastric cancer.2025Cancer letters
  7. De-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming.2025Cell death & diseaseFree full text
  8. Phytosphingosine suppresses gastric cancer through SFRP4/β-catenin axis-mediated Wnt signaling pathway inhibition.2025Chemico-biological interactions
  9. Development of a Risk Prediction Model for Preoperative Pre-Frailty in Elderly Patients with Gastric Cancer.2025Clinical interventions in agingFree full text
  10. Comprehensive Analysis of the ADCY Family and Identification of ADCY5 as a Prognostic Marker for Gastric Cancer.2025Frontiers in bioscience (Landmark edition)
  11. Prognostic performance of examined lymph nodes, lymph node ratio, and positive lymph nodes in gastric cancer: a competing risk model study.2025Frontiers in endocrinologyFree full text
  12. Immune analysis according to Lauren type for gastric cancer and its significance in individual treatment and prognostic prediction.2025Frontiers in immunologyFree full text
  13. Comprehensive pan-cancer analysis of USP35 and validation of its role in gastric cancer.2025Human genomicsFree full text
  14. Microsatellite-Stable Gastric Cancer Can be Classified into 2 Molecular Subtypes with Different Immunotherapy Response and Prognosis Based on Gene Sequencing and Computational Pathology.2025Laboratory investigation; a journal of technical methods and pathology
  15. Primary solitary fibrous tumor of the stomach: A case report and a review of literature.2025MedicineFree full text
  16. Advances in 16S rRNA-Based Microbial Biomarkers for Gastric Cancer Diagnosis and Prognosis.2025Microbial biotechnologyFree full text
  17. T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers.2025Nature communicationsFree full text
  18. The interplay between oxytocin receptor and YAP in regulating gastric cancer progression.2025Oncogene
  19. Machine learning reveals glycolytic key gene in gastric cancer prognosis.2025Scientific reportsFree full text
  20. Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance.2025Seminars in oncology
  21. Gastric Cancer Models Developed via GelMA 3D Bioprinting Accurately Mimic Cancer Hallmarks, Tumor Microenvironment Features, and Drug Responses.2025Small (Weinheim an der Bergstrasse, Germany)
  22. Nanomechanical Analysis of Living Small Extracellular Vesicles to Identify Gastric Cancer Cell Malignancy Based on a Biomimetic Peritoneum.2024ACS nanoFree full text
  23. Frailty as a predictor of adverse outcomes in patients with gastric cancer: A systematic review and meta-analysis of 75,357 patients.2024Ageing research reviews
  24. Integrating transcriptomic data and digital pathology for NRG-based prediction of prognosis and therapy response in gastric cancer.2024Annals of medicineFree full text
  25. Radiomics analysis in predicting vascular invasion in gastric cancer based on enhanced CT: a preliminary study.2024BMC cancerFree full text
  26. Effect of prehabilitation for patients undergoing gastric cancer surgery: a protocol of a systematic review and meta-analysis.2024BMJ openFree full text
  27. Mechanisms of HIF1A-mediated immune evasion in gastric cancer and the impact on therapy resistance.2024Cell biology and toxicologyFree full text
  28. Interpretable multi-modal artificial intelligence model for predicting gastric cancer response to neoadjuvant chemotherapy.2024Cell reports. MedicineFree full text
  29. Deep learning and machine learning approaches to classify stomach distant metastatic tumors using DNA methylation profiles.2024Computers in biology and medicine
  30. Causal relationships between coffee intake, apolipoprotein B and gastric, colorectal, and esophageal cancers: univariable and multivariable Mendelian randomization.2024European journal of nutrition
  31. LOXL1 promotes gastric cancer progression by β-catenin-cyclinD mediated proliferation.2024Experimental cell research
  32. Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy.2024Frontiers in immunologyFree full text
  33. TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer.2024International immunopharmacology
  34. A bibliometric analysis of gastric cancer liver metastases: advances in mechanisms of occurrence and treatment options.2024International journal of surgery (London, England)Free full text
  35. Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer.2024Journal of experimental & clinical cancer research : CRFree full text
  36. Gastric intestinal metaplasia: progress and remaining challenges.2024Journal of gastroenterology
  37. Hypoxia-induced LAMB2-enriched extracellular vesicles promote peritoneal metastasis in gastric cancer via the ROCK1-CAV1-Rab11 axis.2024Oncogene
  38. Prognostic and predictive value of pathohistological features in gastric cancer and identification of SLITRK4 as a potential biomarker for gastric cancer.2024Scientific reportsFree full text
  39. Circulating long noncoding RNA, Zfpm2-As1, and XIST based on medical data analysis are potential plasma biomarkers for gastric cancer diagnosis.2024Technology and health care : official journal of the European Society for Engineering and MedicineFree full text
  40. Alternative Splicing Factor Heterogeneous Nuclear Ribonucleoprotein U as a Promising Biomarker for Gastric Cancer Risk and Prognosis with Tumor-Promoting Properties.2024The American journal of pathology
  41. Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgery
  42. CRIP1 Reshapes the Gastric Cancer Microenvironment to Facilitate Development of Lymphatic Metastasis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  43. Individualized Choice of Simultaneous Cholecystectomy in Patients with Gastric Cancer: A Systematic Review and Meta-analysis.2023Annals of surgical oncology
  44. ASO Author Reflections: The Safety Analysis and Potential Indications of Simultaneous Cholecystectomy for Gastric Cancer.2023Annals of surgical oncology
  45. Association of perioperative allogeneic blood transfusions and long-term outcomes following radical surgery for gastric and colorectal cancers: systematic review and meta-analysis of propensity-adjusted observational studies.2023BJS openFree full text
  46. Expression characteristics and their functional role of IGFBP gene family in pan-cancer.2023BMC cancerFree full text
  47. Long noncoding RNA PSMA3-AS1 functions as a competing endogenous RNA to promote gastric cancer progression by regulating the miR-329-3p/ALDOA axis.2023Biology directFree full text
  48. Characterization of RNA modifications in gastric cancer to identify prognosis-relevant gene signatures.2023Cancer medicineFree full text
  49. Towards an optimal model for gastric cancer peritoneal metastasis: current challenges and future directions.2023EBioMedicineFree full text
  50. Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips.2023EBioMedicineFree full text
  51. Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study.2023Expert review of anticancer therapy
  52. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis.2023Nature communicationsFree full text
  53. Prognostic values of myosteatosis for overall survival in patients with gastric cancers: A meta-analysis with trial sequential analysis.2023Nutrition (Burbank, Los Angeles County, Calif.)
  54. circDYRK1A tethers biological behaviors of gastric carcinoma using novel bioinformatics analysis and experimental validations.2023Scientific reportsFree full text
  55. Deep Learning-Based Stratification of Gastric Cancer Patients from Hematoxylin and Eosin-Stained Whole Slide Images by Predicting Molecular Features for Immunotherapy Response.2023The American journal of pathology
  56. FN1 mRNA 3'-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3'-UTR-let-7i-5p-THBS1 axis.2023TheranosticsFree full text
  57. Leveraging existing 16S rRNA microbial data to identify diagnostic biomarker in Chinese patients with gastric cancer: a systematic meta-analysis.2023mSystemsFree full text
  58. Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis.2022Annals of surgical oncology
  59. ASO Author Reflections: Chemoradiotherapy Versus Chemotherapy, Which One Is Better for Resectable Gastric Cancer Patients?2022Annals of surgical oncology
  60. ASO Author Reflections: Clinical Research and Application Prospect of HIPEC Combined with Surgery in Advanced Gastric Cancer.2022Annals of surgical oncology
  61. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages.2022Annals of surgical oncology
  62. Abnormally Expressed lncRNAs as Potential Biomarkers for Gastric Cancer Risk: A Diagnostic Meta-Bioinformatics Analysis.2022BioMed research internationalFree full text
  63. Hsa_circ_0005230 is up-regulated and promotes gastric cancer cell invasion and migration via regulating the miR-1299/RHOT1 axis.2022BioengineeredFree full text
  64. RBMS1 promotes gastric cancer metastasis through autocrine IL-6/JAK2/STAT3 signaling.2022Cell death & diseaseFree full text
  65. Gastric Organoids: Progress and Remaining Challenges.2022Cellular and molecular gastroenterology and hepatologyFree full text
  66. Kang-Ai Injection Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway.2022Chinese journal of integrative medicine
  67. HER2-Negative Schnitzler Metastasis to the Rectum Detected Using 18 F-FDG PET/CT.2022Clinical nuclear medicine
  68. Discordant Metabolic Response on 18F-FDG PET/CT in Synchronous Primary Gastric Lymphoma and Gastric Adenocarcinoma.2022Clinical nuclear medicineFree full text
  69. Site-Specific Hypermethylation of SST 1stExon as a Biomarker for Predicting the Risk of Gastrointestinal Tract Cancers.2022Disease markersFree full text
  70. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma.2022European journal of medical researchFree full text
  71. Predicting functional circular RNA-based competitive endogenous RNA network in gastric carcinoma using novel bioinformatics analysis.2022Experimental biology and medicine (Maywood, N.J.)Free full text
  72. PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis.2022Frontiers in immunologyFree full text
  73. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.2022Frontiers in immunologyFree full text
  74. Sarcopenia and a 5-mRNA risk module as a combined factor to predict prognosis for patients with stomach adenocarcinoma.2022Genomics
  75. RBPMS2, as a novel biomarker for predicting lymph node metastasis, guides therapeutic regimens in gastric cancer.2022Human cell
  76. Involvement of CXCL17 and GPR35 in Gastric Cancer Initiation and Progression.2022International journal of molecular sciencesFree full text
  77. GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma.2022Journal of experimental & clinical cancer research : CRFree full text
  78. Identification of specific role of SNX family in gastric cancer prognosis evaluation.2022Scientific reportsFree full text
  79. Primary gastric melanoma with pancreatic metastasis: a case report.2021Annals of palliative medicine
  80. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.2021BMC cancerFree full text
  81. Central lymph node metastasis is predictive of survival in advanced gastric cancer patients treated with D2 lymphadenectomy.2021BMC gastroenterologyFree full text
  82. Ubiquitin-associated protein 2 like (UBAP2L) enhances growth and metastasis of gastric cancer cells.2021BioengineeredFree full text
  83. High expression of COL5A2, a member of COL5 family, indicates the poor survival and facilitates cell migration in gastric cancer.2021Bioscience reportsFree full text
  84. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.2021Cellular & molecular biology lettersFree full text
  85. Circ_0049447 acts as a tumor suppressor in gastric cancer through reducing proliferation, migration, invasion, and epithelial-mesenchymal transition.2021Chinese medical journalFree full text
  86. Different clinicopathologic features and prognostic significance of signet ring cell histology in early and locally advanced gastric cancer patients.2021Clinics and research in hepatology and gastroenterology
  87. Inhibitors Targeting YAP in Gastric Cancer: Current Status and Future Perspectives.2021Drug design, development and therapyFree full text
  88. Prognostic significance of palliative gastrectomy in incurable advanced gastric cancer: a retrospective cohort study and meta-analysis.2021European review for medical and pharmacological sciences
  89. Differentiated/undifferentiated mixed type is a prognostic factor for T2/T3 gastric cancer patients.2021Expert review of gastroenterology & hepatology
  90. Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.2021Expert review of molecular diagnostics
  91. Bufalin inhibits peritoneal dissemination of gastric cancer through endothelial nitric oxide synthase-mitogen-activated protein kinases signaling pathway.2021FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  92. A Dynamic Transcriptome Map of Different Tissue Microenvironment Cells Identified During Gastric Cancer Development Using Single-Cell RNA Sequencing.2021Frontiers in immunologyFree full text
  93. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.2021Frontiers in immunologyFree full text
  94. Pepsinogen C expression-related lncRNA/circRNA/mRNA profile and its co-mediated ceRNA network in gastric cancer.2021Functional & integrative genomics
  95. Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer.2021Future oncology (London, England)
  96. PDCD4 regulates apoptosis in human peritoneal mesothelial cells and promotes gastric cancer peritoneal metastasis.2021Histology and histopathology
  97. Integrative analysis-based identification and validation of a prognostic immune cell infiltration-based model for patients with advanced gastric cancer.2021International immunopharmacology
  98. Hsa_circ_001988 attenuates GC progression in vitro and in vivo via sponging miR-197-3p.2021Journal of cellular physiology
  99. The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway.2021Journal of clinical laboratory analysisFree full text
  100. Increased Expression of LIPC Is Associated with Aggressive Phenotype of Borrmann Type 4 Gastric Cancer.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  101. LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis.2021Molecular medicine (Cambridge, Mass.)Free full text
  102. Identifying Diagnostic and Prognostic Biomarkers and Candidate Therapeutic Drugs of Gastric Cancer Based on Transcriptomics and Single-Cell Sequencing.2021Pathology oncology research : PORFree full text
  103. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis.2021PloS oneFree full text
  104. Construction of an immune-related gene signature to predict survival and treatment outcome in gastric cancer.2021Science progressFree full text
  105. Positive lymph node ratio is an index in predicting prognosis for remnant gastric cancer with insufficient retrieved lymph node in R0 resection.2021Scientific reportsFree full text
  106. Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer.2021Translational research : the journal of laboratory and clinical medicine
  107. Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis.2021World journal of gastroenterologyFree full text
  108. A novel prognostic model based on epithelial-mesenchymal transition-related genes predicts patient survival in gastric cancer.2021World journal of surgical oncologyFree full text
  109. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.2020Frontiers in immunologyFree full text
Chinese-language papers (not in the count)5
  1. [Progress of individualized precision therapy for peritoneal metastasis in gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Integrated diagnosis and treatment of peritoneal metastasis in gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Call for attention to the value and challenge of liquid biopsy in diagnosis and treatment for peritoneal metastasis of gastric cancer].2024Zhonghua yi xue za zhi
  4. [Recent progress and future prospects of treatment for peritoneal metastasis in gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Standardized implementation of minimally invasive surgery for Siewert Ⅱ esophagogastric junction adenocarcinoma].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status35
  1. Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric CancerStatus unknownNCT05208372Lead sponsorStart 2022-01
  2. Gut Microbiota and MetabonomicsStatus unknownNCT05205187Lead sponsorStart 2022-02
  3. EDLS-clips in Endoscopic Full-thickness ResectionCompletedNCT07305038Lead sponsorStart 2022-03
  4. Multi-center and Multi-modal Deep Learning Study of Gastric CancerStatus unknownNCT05001321Lead sponsorStart 2021-07
  5. SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal CancerNot yet recruitingNCT06666166Lead (inferred)Phase 2Start 2024-12
  6. A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing MethodStatus unknownNCT06100003Lead (inferred)Start 2023-10
  7. Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ CarcinomaStatus unknownNCT04443036Lead (inferred)N/AStart 2020-06
  8. Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric CancerStatus unknownNCT04286711Lead (inferred)Phase 1/Phase 2Start 2020-03
  9. Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal CancerStatus unknownNCT03915171Lead (inferred)N/AStart 2019-03
  10. S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant AscitesStatus unknownNCT03990103Lead (inferred)Phase 2Start 2017-11
  11. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  12. Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related FatigueRecruitingNCT06830018Study siteN/AStart 2025-01
  13. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  14. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Study siteN/AStart 2024-09
  15. To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric CancerRecruitingNCT06504732Study sitePhase 2/Phase 3Start 2024-08
  16. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  17. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  18. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap MethodRecruitingNCT05450835Study siteN/AStart 2022-09
  19. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  20. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaCompletedNCT06585501Study siteStart 2024-08
  21. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  22. Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA SequencingStatus unknownNCT06036563Study siteStart 2023-09
  23. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  24. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  25. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionCompletedNCT04661150Study sitePhase 2Start 2021-03
  26. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Study sitePhase 1Start 2020-07
  27. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  28. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  29. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  30. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  31. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  32. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  33. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma SurgeryStatus unknownNCT02130752Study siteN/AStart 2014-10
  34. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  35. A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric CancerTerminatedNCT01967875Study sitePhase 2Start 2013-07

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 112025

9 hospitals in Shenyang for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led5
  1. FDG PET/CT in a Case of Primary Ewing Sarcoma of the Uterus.2025Clinical nuclear medicine
  2. Mitochondria in skeletal system-related diseases.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  3. Construction and validation of an oxidative-stress-related risk model for predicting the prognosis of osteosarcoma.2023Aging
  4. A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019.2021BMC cancer
  5. The inhibitory effect of CTAB on human osteosarcoma through the PI3K/AKT signaling pathway.2021International journal of oncology
Earlier papers (2016–2020)11
  1. Carboxypeptidase E-ΔN promotes migration, invasiveness, and epithelial-mesenchymal transition of human osteosarcoma cells via the Wnt-β-catenin pathway.2019Biochemistry and cell biology = Biochimie et biologie cellulaire
  2. Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.2019FEBS open bio
  3. LPS promote Osteosarcoma invasion and migration through TLR4/HOTAIR.2019Gene
  4. Marital Status and Survival in Osteosarcoma Patients: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database.2019Medical science monitor : international medical journal of experimental and clinical research
  5. Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro.2019Pathology, research and practice
  6. Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells.2018Cell cycle (Georgetown, Tex.)
  7. Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo.2018Experimental cell research
  8. Long non-coding RNA NEAT1 promotes proliferation, migration and invasion of human osteosarcoma cells.2018International journal of medical sciences
  9. X-linked inhibitor of apoptosis protein inhibitor Embelin induces apoptosis via PI3K/Akt pathway and inhibits invasion in osteosarcoma cells.2018Journal of cancer research and therapeutics
  10. MicroRNA‑106a regulates the proliferation and invasion of human osteosarcoma cells by targeting VNN2.2018Oncology reports
  11. MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 6 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.1%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 222025

3 hospitals in Shenyang for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led6
  1. The efficacy of immunotherapy in the treatment of tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors: a systematic review and meta-analysis.2026Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  2. Age-dependent diminution of female prognostic advantage in gastrointestinal stromal tumors: a retrospective cohort analysis.2025Frontiers in immunology
  3. Impact of Gastrointestinal Bleeding on Prognosis and Associated Risk Factors in Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.2025The American surgeon
  4. The first case of a collision tumor of gastrointestinal stromal tumor and intravascular large B cell lymphoma.2022Annals of hematology
  5. Sarcopenia as a novel prognostic factor in the patients of primary localized gastrointestinal stromal tumor.2022BMC cancer
  6. Genomic Study of Chinese Quadruple-negative GISTs Using Next-generation Sequencing Technology.2021Applied immunohistochemistry & molecular morphology : AIMM
Earlier papers (2016–2020)5
  1. Is endoscopic resection more effective than laparoscopic resection in gastric gastrointestinal stromal tumours?2020European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. What is the clinical significance of the multivariate prediction model for GI stromal tumors with high malignant potential before endoscopic resection?2020Gastrointestinal endoscopy
  3. The epithelioid gastrointestinal stromal tumor with pulmonary metastasis: A rare case report and literature review.2020Medicine
  4. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).2020Pathology oncology research : POR
  5. The assessment of different risk classification systems for gastrointestinal stromal tumors (GISTs): the analytic results from the SEER database.2018Scandinavian journal of gastroenterology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

6 hospitals in Shenyang for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shenyang for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. FDG PET/CT in a Case of Primary Ewing Sarcoma of the Uterus.2025Clinical nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

2 hospitals in Shenyang for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsBispecific & antibody drugsRelapse & resistance
Departments in papersPathology / laboratory medicine
Papers it led4
  1. Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021.2025BMC public healthFree full text
  2. Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis.2025Frontiers in immunologyFree full text
  3. Megalosplenia as an initial manifestation of multiple myeloma with a novel CYLD gene mutation: A case report and literature review.2024MedicineFree full text
  4. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients.2024Oncology researchFree full text
All its trials on ClinicalTrials.gov, any status9
  1. A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple MyelomaStatus unknownNCT05448404Lead sponsorN/AStart 2022-03
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  4. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  5. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingNCT04684108Study sitePhase 1Start 2021-11
  6. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  7. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  8. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  9. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Shenyang for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & infection triggersGenetics & inherited formsDiagnosis & prognosis
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Shenyang for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Shenyang for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Evaluation of Sysmex XN-3000 for Detection of Schistocyte].2022Zhongguo shi yan xue ye xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 6 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 222025

2 hospitals in Shenyang for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

  2. Not yet recruiting
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07699770

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisRelapse preventionAcute attack treatment
Departments in papersNeurologyOphthalmology / neuro-ophthalmology
Papers it led6
  1. Distinct Inflammatory Profiles and Clinical Characteristics of NMOSD: A Comparative Analysis with NMOSD-like and Encephalitis-like MOG-AD.2025Journal of proteome research
  2. Effect of L-Carnitine Level on the Risk of Neuromyelitis Optica Spectrum Disorders: A Two-Sample Mendelian Randomization Study.2025Molecular neurobiology
  3. Blood-based inflammatory protein biomarker panel for the prediction of relapse and severity in patients with neuromyelitis optica spectrum disorder: A prospective cohort study.2024CNS neuroscience & therapeuticsFree full text
  4. Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases.2023Frontiers in immunologyFree full text
  5. Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.2023Journal of neurology
  6. Field synopsis and systematic meta-analyses of genetic association studies in neuromyelitis optica.2021Autoimmunity reviews
All its trials on ClinicalTrials.gov, any status2
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory TrialNot yet recruitingNCT07699770Study sitePhase 4Start 2026-06
  2. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
More papers found outside PubMed (not counted)1
  1. New insights into mapping lesion and neurotransmitter distribution comparisons in MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders2024Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 6 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 2.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

2 hospitals in Shenyang for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment & relapseDiagnosis & look-alikesKidney, retroperitoneum & vessels
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 9 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.8%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 442025

2 hospitals in Shenyang for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisThymus & thymectomyBiologic & complement drugs
Departments in papersNeurologyOphthalmology / neuro-ophthalmologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

1 hospital in Shenyang for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Shenyang for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Pathogenesis of liver injury in Takayasu arteritis: advanced understanding leads to new horizons.2020The Journal of international medical research
All its trials on ClinicalTrials.gov, any status3
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04
  2. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Study sitePhase 3Start 2020-02
  3. Takayasu Arteritis Clinical Trial in ChinaCompletedNCT02981979Study siteN/AStart 2016-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

7 hospitals in Shenyang for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Papers it led3
  1. Ubiquitin-specific peptidase 10 attenuates bleomycin-induced pulmonary fibrosis via modulating autophagy depending on sirtuin 6-mediated AKT/mTOR.2025Cell biology and toxicology
  2. SCARF2 is a target for chronic obstructive pulmonary disease: Evidence from multi-omics research and cohort validation.2024Aging cell
  3. Expression of S100A9 and KL-6 in common interstitial lung diseases.2022Medicine
Earlier papers (2016–2020)4
  1. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.2020Therapeutic advances in respiratory disease
  2. Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis.2019Advances in therapyRCT
  3. Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression.2019Respiratory research
  4. [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].2016Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
All its trials on ClinicalTrials.gov, any status2
  1. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09
  2. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

2 hospitals in Shenyang for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Otological aspects of Fabry disease in patients with normal hearing.2019Nagoya journal of medical science

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Shenyang for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 002025

3 hospitals in Shenyang for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Shenyang for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Shenyang for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou

  3. Recruiting
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    Phase
    Phase 3
    Started
    2023-02
    Registry
    NCT05751967

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led1
  1. S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis.2021World journal of gastroenterology
Earlier papers (2016–2020)1
  1. Identification of Marker Genes and Pathways in Patients with Primary Biliary Cholangitis.2020Journal of computational biology : a journal of computational molecular cell biology
All its trials on ClinicalTrials.gov, any status4
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  3. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary CholangitisRecruitingNCT05751967Study sitePhase 3Start 2023-02
  4. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisActive, not recruitingNCT06174402Study sitePhase 2/Phase 3Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

2 hospitals in Shenyang for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Shenyang for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shenyang for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中国医科大学附属第一医院

First Hospital of China Medical University

沈阳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First Affiliated Hospital of China Medical University; College of Basic Medical Science and The First Affiliated Hospital; College of Basic Medical Sciences and First Affiliated Hospital; and First Affiliated Hospital of China Medical University

Suggest a correctionDownload the data